ACADEMIA
    HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
    By Ken Yoshino October 7, 2026
    Japan should move ahead with routine HPV vaccinations for males by looking at not only the direct benefits for men but also indirect protection for women and broader public health benefits, according to Hideaki Miyake,…

    LATEST

    PeptiDream Earns Milestone Payment from US Merck
    October 8, 2026
    PeptiDream said on October 7 that it will receive an undisclosed milestone payment from US Merck following the achievement of a development milestone under the companies’ ongoing collaboration on peptide cytotoxic conjugates (PCCs).Under the collaboration,…
    Argenx Steps Up Japan Hunt for Drug Discovery Seeds
    October 7, 2026
    Argenx is ratcheting up its drive in Japan to unearth promising drug discovery seeds through its global Immunology Innovation Program (IIP), seeing the country as a key source of potentially untapped innovation.The Belgian immunology specialist…
    SCARDA, Thai Vaccine Institute Link Up on KM Biologics’ Dengue Shot
    October 7, 2026
    Japan’s and Thailand’s key agencies for vaccine R&D and preparedness inked a memorandum of cooperation on October 6, with the two sides set to initially collaborate on the development of KM Biologics’ dengue vaccine candidate…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
    By Takashi Ebisawa

    Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…

    COLUMN

    Outside the Bubble: Lunch with Pharma Delegates
    By Philip Carrigan

    The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA